Guerrero Sandra, Muñíz Enriqueta, Teijón César, Olmo Rosa, Teijón José M, Blanco M Dolores
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
J Pharm Sci. 2008 Aug;97(8):3153-69. doi: 10.1002/jps.21241.
Ketotifen (KT) was encapsulated into poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA 50/50) by spray-drying to investigate the use of biodegradable drug-loaded microspheres as delivery systems in the intraperitoneal cavity. Ketotifen stability was evaluated by HPLC, and degradation was not observed. Drug entrapment efficiency was 74 +/- 7% (82 +/- 8 microg KT/mg for PLA) and 81 +/- 6% (90 +/- 7 microg KT/mg for PLGA 50/50). PLA microspheres released ketotifen (57% of encapsulated KT) in 350 h at two release rates (221 microg/h, 15 min to 2 h; 1.13 microg/h, 5-350 h). A quicker release of ketotifen took place from PLGA 50/50 microspheres (67.4% of encapsulated KT) in 50 h (322 microg/h, 15 min to 2 h; 16.18 microg/h, 5-50 h). After intraperitoneal administration (10 mg KT/kg b.w.), microsphere aggregations were detected in adipose tissue. Ketotifen concentration was determined in plasma by HPLC. The drug released from PLA and PLGA 50/50 microspheres was detected at 384 and 336 h, respectively. Noncompartmental analysis was performed to determine pharmacokinetic parameters. The inclusion of ketotifen in PLGA and PLA microspheres resulted in significant changes in the plasma disposition of the drug. Overall, these ketotifen-loaded microspheres yielded an intraperitoneal drug release that may be suitable for use as delivery systems in the treatment of inflammatory response in portal hypertension.
通过喷雾干燥将酮替芬(KT)包封到聚(D,L-丙交酯)(PLA)和聚(D,L-丙交酯-共-乙交酯)(PLGA 50/50)中,以研究可生物降解的载药微球作为腹腔给药系统的用途。通过高效液相色谱法评估酮替芬的稳定性,未观察到降解。药物包封率分别为74±7%(PLA为82±8μg KT/mg)和81±6%(PLGA 50/50为90±7μg KT/mg)。PLA微球在350小时内以两种释放速率释放酮替芬(包封的KT的57%)(221μg/h,15分钟至2小时;1.13μg/h,5至350小时)。PLGA 50/50微球在50小时内更快地释放酮替芬(包封的KT的67.4%)(322μg/h,15分钟至2小时;16.18μg/h,5至50小时)。腹腔注射(10mg KT/kg体重)后,在脂肪组织中检测到微球聚集。通过高效液相色谱法测定血浆中的酮替芬浓度。从PLA和PLGA 50/50微球释放的药物分别在384小时和336小时被检测到。进行非房室分析以确定药代动力学参数。将酮替芬包封在PLGA和PLA微球中导致药物血浆处置的显著变化。总体而言,这些载酮替芬微球产生的腹腔内药物释放可能适合用作治疗门静脉高压症炎症反应的给药系统。